This latest award from the CDTI and Spanish Ministry Mineco represents substantial further support for Peptomyc’s mission and will help in the development of OMO-101 and its derivative OMO-103. The project is titled “Pre-clinical development of Myc-inhibiting peptides to treat cancer” (“Desarrollo pre-clínico de péptidos inhibidores de Myc para el tratamiento de cáncer”) and counts on the collaboration of Granzer and Ciemat.

The award is from the NEOTEC program, aimed at new small businesses that are developing innovative technologies. This support will help to cement Peptomyc’s position as a world leader in the development of direct Myc inhibitors and put Spain at the forefront of innovative therapies.